Knight Therapeutics Inc. (TSE:GUD - Get Free Report) hit a new 52-week high on Tuesday . The company traded as high as C$6.25 and last traded at C$6.18, with a volume of 43828 shares changing hands. The stock had previously closed at C$6.17.
Analysts Set New Price Targets
Separately, Research Capitl raised Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, March 11th. Two investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Knight Therapeutics currently has a consensus rating of "Strong Buy" and a consensus price target of C$7.08.
Check Out Our Latest Stock Analysis on Knight Therapeutics
Knight Therapeutics Trading Down 1.4 %
The company has a market cap of C$625.11 million, a P/E ratio of -20.63, a PEG ratio of -1,013.50 and a beta of 0.50. The company has a current ratio of 3.36, a quick ratio of 1.79 and a debt-to-equity ratio of 7.52. The stock's 50 day moving average is C$5.68 and its 200-day moving average is C$5.58.
Insider Activity at Knight Therapeutics
In related news, insider Sime Armoyan sold 92,200 shares of Knight Therapeutics stock in a transaction dated Monday, March 17th. The stock was sold at an average price of C$6.15, for a total value of C$567,030.00. In the last three months, insiders have sold 643,300 shares of company stock valued at $3,983,740. 45.62% of the stock is owned by corporate insiders.
Knight Therapeutics Company Profile
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
See Also
Before you consider Knight Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Knight Therapeutics wasn't on the list.
While Knight Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
